GenVec Inc (GNVC) was Resumed by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $2.30. Rodman & Renshaw advised their investors in a research report released on Jun 20, 2016.
Many Wall Street Analysts have commented on GenVec Inc. Rodman & Renshaw Resumed GenVec Inc on Jun 20, 2016 to “Buy”, Price Target of the shares are set at $2.30.
GenVec Inc opened for trading at $0.63 and hit $0.64 on the upside on Friday, eventually ending the session at $0.636, with a gain of 2.58% or 0.016 points. The heightened volatility saw the trading volume jump to 51,704 shares. Company has a market cap of $14 M.
In a different news, on Dec 15, 2015, Douglas J Swirsky (CEO) purchased 5,000 shares at $2.00 per share price. According to the SEC, on Nov 18, 2015, Stefan Loren (director) purchased 4,000 shares at $1.93 per share price. On Aug 11, 2015, Douglas E Brough (Chief Scientific Officer) purchased 4,600 shares at $2.34 per share price, according to the Form-4 filing with the securities and exchange commission.
GenVec Inc. (GenVec) is a clinical-stage biopharmaceutical company engaged in the development of therapeutics and vaccines. The Company designs tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas such as hearing loss and balance disorders as well as vaccines against infectious diseases including respiratory syncytial virus (RSV) herpes simplex virus (HSV) Enterovirus D68 (EV-D68) and malaria. The Company develops and commercializes its product candidates through collaborations. In collaboration with Novartis the Company’s hearing and balance disorders program is involved in the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. In the area of animal health the Company with its collaborators is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.